Rabbit Anti-C1S Recombinant Antibody (CBFYC-0612) (CBMAB-C0666-FY)

Daugan, M., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., ... & Roumenina, L. (2021). Complement C1s and C4d as prognostic biomarkers in renal cancer: emergence of non-canonical functions of C1s. Cancer Immunology Research, canimm-0532.

Azasi, Y., Low, L. M., Just, A. N., Raghavan, S. S., Wang, C. W., Valenzuela-Leon, P., ... & Miller, L. H. (2021). Complement C1s cleaves PfEMP1 at interdomain conserved sites inhibiting Plasmodium falciparum cytoadherence. Proceedings of the National Academy of Sciences, 118(22).

Gelbenegger, G., Schoergenhofer, C., Derhaschnig, U., Buchtele, N., Sillaber, C., Fillitz, M., ... & Jaeger, U. (2020). Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood advances, 4(6), 997-1005.

Riihilä, P., Viiklepp, K., Nissinen, L., Farshchian, M., Kallajoki, M., Kivisaari, A., ... & Kähäri, V. M. (2020). Tumour‐cell‐derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. British Journal of Dermatology, 182(3), 658-670.

Fouët, G., Gout, E., Wicker-Planquart, C., Bally, I., De Nardis, C., Dedieu, S., ... & Rossi, V. (2020). Complement C1q Interacts with LRP1 Clusters II and IV Through a Site Close but Different From the Binding Site of Its C1r and C1s-Associated Proteases. Frontiers in immunology, 11, 2706.

Jäger, U., D’Sa, S., Schörgenhofer, C., Bartko, J., Derhaschnig, U., Sillaber, C., ... & Jilma, B. (2019). Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood, The Journal of the American Society of Hematology, 133(9), 893-901.

Röth, A., Barcellini, W., D'Sa, S., Miyakawa, Y., Broome, C. M., Michel, M., ... & Berentsen, S. (2019). Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): results from the phase 3 cardinal study. Blood, 134, LBA-2.

Nikitin, P. A., Rose, E. L., Byun, T. S., Parry, G. C., & Panicker, S. (2019). C1s inhibition by BIVV009 (Sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in vitro. The Journal of Immunology, 202(4), 1200-1209.

Almitairi, J. O., Girija, U. V., Furze, C. M., Simpson-Gray, X., Badakshi, F., Marshall, J. E., ... & Wallis, R. (2018). Structure of the C1r–C1s interaction of the C1 complex of complement activation. Proceedings of the National Academy of Sciences, 115(4), 768-773.

Chen, J. J., Schmucker, L. N., & Visco, D. P. (2018). Pharmaceutical machine learning: virtual high-throughput screens identifying promising and economical small molecule inhibitors of complement factor C1s. Biomolecules, 8(2), 24.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols